233 related articles for article (PubMed ID: 32206560)
1. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
[TBL] [Abstract][Full Text] [Related]
2. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
Taniguchi Y; Horiuchi H; Morikawa T; Usui K
Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
4. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
[TBL] [Abstract][Full Text] [Related]
5. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
[TBL] [Abstract][Full Text] [Related]
7. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
8. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.
Zhou Y; Bai H; Xia J; Xu WY; Cheng L; Xiong L
Ann Transl Med; 2021 Jul; 9(14):1150. PubMed ID: 34430591
[TBL] [Abstract][Full Text] [Related]
9. Primary resistance to osimertinib despite acquired
Chang LK; Chang YL; Shih JY
Respirol Case Rep; 2020 Mar; 8(2):e00532. PubMed ID: 32042433
[TBL] [Abstract][Full Text] [Related]
10. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
11. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
Zhang Y; He B; Zhou D; Li M; Hu C
Onco Targets Ther; 2019; 12():51-56. PubMed ID: 30588029
[TBL] [Abstract][Full Text] [Related]
12. Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.
Yamaguchi F; Kato E; Wakabayashi A; Shikama Y
Mol Clin Oncol; 2019 Aug; 11(2):127-131. PubMed ID: 31316771
[TBL] [Abstract][Full Text] [Related]
13. Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review.
Chen X; Li D; Miao K; Shou T; Zhang W
Medicine (Baltimore); 2023 Jan; 102(4):e32697. PubMed ID: 36705363
[TBL] [Abstract][Full Text] [Related]
14. Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
Nishioka N; Yamada T; Harita S; Hirai S; Katayama Y; Nakano T; Okura N; Tamiya N; Kaneko Y; Uchino J; Takayama K
Respir Med Case Rep; 2018; 25():261-263. PubMed ID: 30310765
[TBL] [Abstract][Full Text] [Related]
15. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report.
Hong E; Chen XE; Mao J; Zhou JJ; Chen L; Xu JY; Tao W
World J Clin Cases; 2022 Mar; 10(9):2836-2843. PubMed ID: 35434119
[TBL] [Abstract][Full Text] [Related]
16. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.
Fang L; He J; Xia J; Dong L; Zhang X; Chai Y; Li Y; Niu M; Hang T; Li S
Oncol Lett; 2017 Jul; 14(1):593-598. PubMed ID: 28693210
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
[TBL] [Abstract][Full Text] [Related]
18. A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy.
Hirakawa H; Komiya K; Nakashima C; Ogusu S; Nakamura T; Tanaka M; Takahashi K; Egashira Y; Kai K; Kimura S; Sueoka-Aragane N
Ann Transl Med; 2018 Dec; 6(23):464. PubMed ID: 30603652
[TBL] [Abstract][Full Text] [Related]
19. A "triple whammy" in adenocarcinoma lung.
Patro M; Gothi D; Vaidya S; Sah RB
Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
[TBL] [Abstract][Full Text] [Related]
20. Squamous cell transformation and
Bruno R; Proietti A; Alì G; Puppo G; Ribechini A; Chella A; Fontanini G
Oncol Lett; 2017 Nov; 14(5):5947-5951. PubMed ID: 29113230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
